Highlights•Case-control study to identify risk factors for carbapenemase-producing
Klebsiella pneumoniae fecal carriage.•This study included 87 cases, 200 controls …

Background: Plasma concentrations of trastuzumab< 20 µg/mL in patients with gastric
cancer are associated with reduced progression-free and overall survival. In breast cancer …

This paper describes a general methodology for developing parallel image processing
algorithms based on message passing for high resolution images (on the order of several …

Colorectal cancer is the second most common cancer in Europe. Most antineoplastic
regimens in first-line treatment involve 5-fluorouracil or oral prodrug capecitabine, combined …

Background: Subcutaneous trastuzumab (T-SC) administration does not allow the historical
target concentration of 20 µg/mL for efficacy to be reached, from the start of treatment in …

Introduction The advent of Luer-type needleless venous access catheters has been
accompanied by a growing number of catheter-related bloodstream infections. Our main …

Introduction Limited therapeutic options and high mortality make the management of OXA-
48-like carbapenemase-producing Klebsiella pneumoniae (KPOXA-48) bacteraemia …

Introduction Trastuzumab is a monoclonal antibody which could induce the activation of a
humoral immune response generating anti-drug antibodies (ADAs). Such response …

Results: The PFS obtained in clinical trials with cis/pem, cis/gem/bev and carb/pac/bev was:
6.9, 6.7 and 6.2 months, res-pectively. Based on our model, the mean cost of treatment per …

Objective The present work analyzed the stability of trastuzumab concentrations in blood
and plasma samples stored at 4° C and–; 20° C. Method Blood samples of patients treated …